Research Insights Episodes

We're at the American Academy of Neurology Annual Meeting in Philadelphia, and we're talking about teleneurology, stem cells, a new algorithm, and a new research network with ambitious goals. Today, it's a real peek into the future! We have a lot to talk about! Are you ready for RealTalk MS??!

Get the latest news from the American Academy of Neurology Annual Meeting. We're looking into the future of applying precision medicine to treat MS. We're talking about an artificial intelligence application that's designed to predict the course of your MS and recommend the best treatment plan for you We'll also tell you about a "digital prescription therapeutic" designed to treat depression in people living with MS. And researchers are also looking at better understanding the recent past, as a...

It's my first day at the American Academy of Neurology Annual Meeting, and we're talking about a great presentation on Progress in Progressive MS and some eye-opening news about the amount of money we're spending in the U.S. on prescription drugs to treat neurological conditions.

My guest this week is Yvette Brisco. Yvette is an MS activist and an MS warrior. And when Yvette talks about the fight to find a cure, she means it literally! We're also talking about the European Medicine Agency's safety review of Lemtrada. We'll tell you about the 20 million American caregivers who are performing medical or nursing tasks for which they've received no training. We'll give you a real-world example of why people living with MS (or anyone else) living in a care facility need an a...

Robots?? Really??? The answer is YES! World renowned robotics expert Dr. Maja Mataric joins us on the podcast, and we're talking about how socially assistive robots could be real game-changers for people living with MS and other chronic conditions, as well as their caregivers. We're also talking about the $24.4 million investment by the National MS Society that will support 64 new MS research projects. We'll tell you about the research team at Oregon Health & Science University that believes th...

March 28th is Progressive MS Day. While only about 15% of the people diagnosed with MS are initially given a diagnosis of Primary Progressive MS, about 65% of the people who are diagnosed with relapsing-remitting MS will eventually develop Secondary Progressive MS. And the difference between progressive MS and relapsing-remitting MS is that, usually, people diagnosed with Progressive MS don't experience any remission in their disease progression. Their MS just seems to worsen more steadily over ...

MS is an equal opportunity neurological disease. It doesn't seem to discriminate against any particular ethnic or racial group. It affects Latinos and African-Americans, as well as Caucasians. And if you're an MS research scientist, who's hoping to create a viable treatment that's going to be safe & effective for the diverse population living with multiple sclerosis, then having that diversity represented in your clinical research seems like it would be important. Unfortunately, it doesn't alway...

It's MS Awareness Week! And the single event that is likely going to have the most impact in raising awareness of MS in the United States is the recent announcement of the MS Prevalence Study results. The results of this study corrected the decades old notion that there were only about 400,000 people living with MS in the United States. We now know that the number of people living with MS in the U.S. is closer to one million. More than twice as many as had been previously estimated. In this sp...

One of the fundamental questions on the minds of just about everyone living with MS is How did I get it? What causes MS? It's a question that's still awaiting a definitive answer. But as we wait for that answer, science is uncovering more and more information about MS risk factors -- the things that can make living with MS better or worse. My guest is Dr. Farren Briggs, an epidemiologist who's focused on the etiology, or the cause of multiple sclerosis, and the risk factors that actually impact...

We know about the importance of disease-modifying therapy (DMT) in managing MS and slowing its progression. But you may not know that there are two very different schools of thought when it comes to how and why your neurologist may recommend one DMT over another. My guest is Dr. Aaron Boster, the System Medical Chief for Neuroimmunology at OhioHealth, and we're talking about an important conversation that you should be having with your neurologist. We're also talking about the newly published c...